Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Probucol (compound)

Summary
General Info

PubChem

PubChem Compound 4912

PubChem Compound 4912

Name:	Probucol
PubChem Compound ID:	4912
Description:	A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Molecular formula:	C₃₁H₄₈O₂S₂
Molecular weight:	516.844 g/mol
Synonyms:	KBioGR_000708; EINECS 245-560-9; Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-; NCGC00016777-01; Probucol; KBio1_000599; D00476; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Bisbid; Spectrum2_001400. show more » KBioGR_000708; EINECS 245-560-9; Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-; NCGC00016777-01; Probucol; KBio1_000599; D00476; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Bisbid; Spectrum2_001400; CAS-23288-49-5; Lurselle; C07373; 23288-49-5; NSC86225; Phenol, 4,4'-((1-methylethylidene)bis(thio))bis(2,6-bis(1,1-dimethylethyl)-; 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]; Biphenabid; 4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol); Spectrum3_001438; Spectrum_001296; MLS000028492; Panavir; DH-581; Probucol (JAN/USP); SPBio_001420; DE-3872; KBio2_001776; KBio2_004962; Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; SMR000058265; Prestwick_408; Lorelco; KBioSS_001776; Prestwick1_000384; Prestwick0_000384; Lorelco (TN); Lursell; Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Probucolum [INN-Latin]; KBio2_006912; NSC652160; NSC 86225; Spectrum4_000414; NSC 652160; KBio3_002873; KBioGR_002394; AIDS027579; KBioSS_002399; BRN 2026253; KBio2_002394; KBio3_002396; DH 581; SPBio_002488; DivK1c_000599; Phenol, 4, 4'-[ (1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-; CCRIS 7510; Probucol [USAN:BAN:INN:JAN]; 4,4'- (Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); ZERO/001429; Sinlestal; KBio2_004344; AIDS-027579; NINDS_000599; Lesterol; KBio2_007530; Bisphenabid; ZINC01530755 show less «

DrugBank

Identification

Name:	Probucol
Name (isomeric):	DB01599
Drug Type:	small molecule
Description:	A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Synonyms:	4,4'- (Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]; Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; 4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol); Probucolum [inn-latin]; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; 4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
Brand:	Bisbid, Lursell, Sinlestal, Panavir, Bisphenabid, Lorelco, Lesterol, Biphenabid, Lurselle
Category:	Antioxidants, Anticholesteremic Agents
CAS number:	23288-49-5

Pharmacology

Indication:	Used to lower LDL and HDL cholesterol.
Pharmacology:	Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption. Probucol is a powerful antioxidant drug normally used to prevent vascular disease caused by the free radicals in the body.
Mechanism of Action:	Probucol lowers serum cholesterol by increasing the fractional rate of low-density lipoprotein (LDL) catabolism in the final metabolic pathway for cholesterol elimination from the body. Additionally, probucol may inhibit early stages of cholesterol biosynthesis and slightly inhibit dietary cholesterol absorption. Recent information suggests that pr... show more » Probucol lowers serum cholesterol by increasing the fractional rate of low-density lipoprotein (LDL) catabolism in the final metabolic pathway for cholesterol elimination from the body. Additionally, probucol may inhibit early stages of cholesterol biosynthesis and slightly inhibit dietary cholesterol absorption. Recent information suggests that probucol may inhibit the oxidation and tissue deposition of LDL cholesterol, thereby inhibiting atherogenesis. It appears to inhibits ABCA1-mediated cellular lipid efflux. show less «
Absorption:	Absorption from the gastrointestinal tract is limited and variable (about 7%).
Half Life:	Ranges from 12 hours to more than 500 hours, the longest half-life probably being in adipose tissue.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Take with food. Food increases availability.

Drug interaction:

Tacrolimus	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Lumefantrine	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Thiothixene	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
Vorinostat	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Toremifene	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.

Targets

ATP-binding cassette sub-family A member 1

Liver carboxylesterase 1